Soheil Meshinchi MD PhD
Cancer Genetics/Cancer Risk Assessment
- Member, Fred Hutchinson Cancer Research Center - Professor of Pediatrics, University of Washington School of Medicine
Join to view full profile
Fred Hutchinson Cancer Research Center1100 Fairview Ave NSeattle, WA 98109
Phone+1 206-667-4077
Dr. Meshinchi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Soheil Meshinchi, MD, PhD, is a Full Member at Fred Hutchinson Cancer Center and Professor of Pediatrics at the University of Washington, specializing in acute myeloid leukemia (AML).
His research uses genomic, epigenomic, and proteomic profiling to uncover the biology of childhood AML and identify vulnerabilities that can be targeted therapeutically. A central focus is the discovery of AML-restricted antigens and their translation into immunotherapies, including CAR T-cell therapies and TCR-mimic approaches directed at intracellular targets. By advancing discoveries from molecular characterization through preclinical development and clinical trials, he aims to expand effective treatment options for children with high-risk leukemia.
Education & Training
University of WashingtonFellowship, Pediatric Hematology/Oncology, 1997 - 2000
Johns Hopkins UniversityResidency, Pediatrics, 1994 - 1997
Wayne State University School of MedicineClass of 1994
The University of Michigan School of MedicinePh.D., 1985 - 1990- University of MichiganPh.D., Pharmacology, 1985 - 1990
Certifications & Licensure
WA State Medical License 1998 - 2026
Clinical Trials
Publications & Presentations
PubMed
- Reactive oxygen species define leukemia stem cell identity in pediatric acute myeloid leukemia.Maddalena Benetton, Ambra Da Ros, Alberto Peloso, Giorgia Longo, Sara Perpinello
Cancer Letters. 2026-11-28 - Prognostic impact of age and MDS-associated mutations in-mutated AML.Vivian M Liu, Megan Othus, Jasmine Naru, Rhonda E Ries, Era L Pogosova-Agadjanyan
Blood Neoplasia. 2026-11-01 - CBFA2T3-GLIS2 establishes transcriptionally permissive enhancer hypermethylation associated with venetoclax response in pediatric AML.Arundhati Chavan, Rhonda Ries, Pritam Biswas, Jason E Farrar, Soheil Meshinchi
Biorxiv. 2026-10-08
Journal Articles
- Acute Myeloid Leukemia in Children and Adolescents: Identification of New Molecular Targets Brings Promise of New TherapiesSoheil Meshinchi, MD, Hematology ASH Education Program
- Prognostic Impact of T(16;21)(p11;q22) and T(16;21)(q24;q22) in Pediatric AML: A Retrospective Study by the I-BFM Study GroupSoheil Meshinchi, Tanja A Gruber, Blood
- Pan-cancer Genome and Transcriptome Analyses of 1,699 Pediatric Leukemias and Solid TumorsMa X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pou..., Nature Medicine, 1/1/2018
Books/Book Chapters
Abstracts/Posters
- In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid LeukemiaSoheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational ProfileSoheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous...Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML05312018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Tip Sheet: New Insights on RSV and Malaria, Metastatic Breast Cancer Resources for Patients — and Fred Hutch at ASHDecember 5th, 2024
New Initiative Bolsters Washington State Life SciencesNovember 19th, 2024
Sutro Biopharma Announces Initiation of the Registration-Enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLNovember 1st, 2024
Grant Support
- Pediatric Oncology Research Training ProgramFRED HUTCHINSON CANCER CENTER1979–2027
- Pediatric Oncology Research Training ProgramFRED HUTCHINSON CANCER CENTER1979–2027
- COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in ChildrenPUBLIC HEALTH INSTITUTE2022–2026
- Career Development in Pediatric and Medical OncologyFRED HUTCHINSON CANCER CENTER1997–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: